West Pharm sales fall short

The maker of packaging and delivery devices for drugs and related consumer products said Q4 EPS climbed 22.6% to 38 cents, in line with estimates. Revenue rose 7.8% to $346.6 mil, below projections for $348.7 mil. West Pharmaceutical (WST) forecast full-year '14 EPS of $1.75- $1.89, the midpoint less than analyst views for $1.87. The board appointed a new director and announced a 10-cent per share dividend in Q2. Shares rose 1.4% to 48.42.